133 related articles for article (PubMed ID: 16472782)
1. Estrogen and CCK1 receptor modification of mu-opioid receptor binding in the cortex of female rats.
Quesada A; Micevych P
Brain Res; 2006 Feb; 1073-1074():316-20. PubMed ID: 16472782
[TBL] [Abstract][Full Text] [Related]
2. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
3. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
4. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
5. Role of fluidity of membranes on the guanyl nucleotide-dependent binding of cholecystokinin-8S to rat brain cortical membranes.
Rinken A; Harro J; Engström L; Oreland L
Biochem Pharmacol; 1998 Feb; 55(4):423-31. PubMed ID: 9514076
[TBL] [Abstract][Full Text] [Related]
6. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
7. Colocalization of mu-opioid receptors and activated G-proteins in rat cingulate cortex.
Vogt LJ; Sim-Selley LJ; Childers SR; Wiley RG; Vogt BA
J Pharmacol Exp Ther; 2001 Dec; 299(3):840-8. PubMed ID: 11714867
[TBL] [Abstract][Full Text] [Related]
8. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
Bignon E; Bachy A; Boigegrain R; Brodin R; Cottineau M; Gully D; Herbert JM; Keane P; Labie C; Molimard JC; Olliero D; Oury-Donat F; Petereau C; Prabonnaud V; Rockstroh MP; Schaeffer P; Servant O; Thurneyssen O; Soubrié P; Pascal M; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1999 May; 289(2):742-51. PubMed ID: 10215648
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic opioid exposure on guinea pig mu opioid receptor in Chinese hamster ovary cells: comparison with human and rat receptor.
Wallisch M; Nelson CS; Mulvaney JM; Hernandez HS; Smith SA; Olsen GD
Biochem Pharmacol; 2007 Jun; 73(11):1818-28. PubMed ID: 17343833
[TBL] [Abstract][Full Text] [Related]
10. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
11. Cholecystokinin-GABA interactions in rat striatum.
Rakovska A
Neuropeptides; 1995 Nov; 29(5):257-62. PubMed ID: 8587661
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin octapeptide induces endogenous opioid-dependent anxiolytic effects in morphine-withdrawal rats.
Wen D; Sun D; Zang G; Hao L; Liu X; Yu F; Ma C; Cong B
Neuroscience; 2014 Sep; 277():14-25. PubMed ID: 24993476
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
[TBL] [Abstract][Full Text] [Related]
14. Antinociception following application of DAMGO to the basolateral amygdala results from a direct interaction of DAMGO with Mu opioid receptors in the amygdala.
Shin MS; Helmstetter FJ
Brain Res; 2005 Dec; 1064(1-2):56-65. PubMed ID: 16289487
[TBL] [Abstract][Full Text] [Related]
15. A cloned CCK-A receptor transduces multiple signals in response to full and partial agonists.
Yule DI; Tseng MJ; Williams JA; Logdson CD
Am J Physiol; 1993 Nov; 265(5 Pt 1):G999-1004. PubMed ID: 8238528
[TBL] [Abstract][Full Text] [Related]
16. Cholecystokinin-GABA interactions in rodent cortex: analyses of cholecystokinin effects on K(+)- and L-glutamate-induced release of [3H]GABA from rat cortical slices and cultured mouse cortical neurones.
Hickling YM; Cheung NS; Larm JA; Cowen MS; Shulkes A; Beart PM
Neurochem Int; 1997 Feb; 30(2):171-9. PubMed ID: 9017664
[TBL] [Abstract][Full Text] [Related]
17. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence.
Xu H; Partilla JS; Wang X; Rutherford JM; Tidgewell K; Prisinzano TE; Bohn LM; Rothman RB
Synapse; 2007 Mar; 61(3):166-75. PubMed ID: 17152090
[TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin receptor-1 mediates the inhibitory effects of exogenous cholecystokinin octapeptide on cellular morphine dependence.
Wen D; Ma CL; Zhang YJ; Meng YX; Ni ZY; Li SJ; Cong B
BMC Neurosci; 2012 Jun; 13():63. PubMed ID: 22682150
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
20. Effect of agmatine on DAMGO-induced mu-opioid receptor down-regulation and internalization via activation of IRAS, a candidate for imidazoline I(1) receptor.
Gao Y; Li F; Wu N; Su RB; Liu Y; Lu XQ; Liu Y; Li J
Eur J Pharmacol; 2008 Dec; 599(1-3):18-23. PubMed ID: 18845140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
